NeuroSense Therapeutics Granted Parent From U.S. Patent And Trademark Office For Use Of PrimeC Combination In Alzheimer' Disease
Benzinga Newsdesk 9 months ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,527,768, entitled "Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases."
The granted patent provides protection for the use of PrimeC combination in Alzheimer's disease, strengthening NeuroSense's intellectual property estate and supporting the program's long-term development and potential commercialization, with protection extending through 2043.
